Abstract Full text links

COVID-19 Information
Public health information (CDC) | Research information (NIH)
SARS-CoV-2 data (NCBI) | Prevention and treatment information (HHS) | Español

Log in

I Search
Advanced

Save Email Send to Display options

Meta-Analysis BMC Cardiovasc Disord. 2017 Jul 24;17(1):196.

doi: 10.1186/s12872-017-0628-9.

Efficacy of coenzyme Q10 in patients with cardiac

failure: a meta-analysis of clinical trials
Li Lei 1 , Yan Liu 2

Affiliations expand
PMID: 28738783 PMCID: PMC5525208 DOI: 10.1186/s12872-017-0628-9
Free PMC article

Full text links Cite

Abstract
Background: The therapeutic efficacy of coenzyme Q10 on patients with cardiac failure remains
controversial. We pooled previous clinical studies to re-evaluate the efficacy of coenzyme Q10 in
patients with cardiac failure.

Methods: We searched PubMed, Cochrane Library, EMBASE, and Clinical Trials.gov databases for
controlled trials. The endpoints were death, left heart ejection fraction, exercise capacity, and New
York Heart Association (NYHA) cardiac function classification after treatment. The pooled risk
ratios (RRs) and standardized mean difference (SMD) were used to assess the efficacy of
coenzyme Q10.

Results: A total of 14 RCTs with 2149 patients met the inclusion criteria and were included in the
analysis. Coenzyme Q10 decreased the mortality compared with placebo (RR = 0.69; 95% CI =
0.50-0.95; P = 0.02; I 2 = 0%). A greater improvement in exercise capacity was established in
patients who used coenzyme Q10 than in those who used placebo (SMD = 0.62; 95% CI = 0.02-
0.30; P = 0.04; I 2 = 54%). No significant difference was observed in the endpoints of left heart
ejection fraction between patients who received coenzyme Q10 and the patients in whom placebo
was administered (SMD = 0.62; 95% CI = 0.02-1.12; P = 0.04; I 2 = 75%). The two types of
treatment resulted in obtaining similar NYHA classification results (SMD = -0.70; 95% CI = -1.92-
0.51; P = 0.26; I 2 = 89%).

Conclusion: Patients with heart failure who used coenzyme Q10 had lower mortality and a higher
exercise capacity improvement than the placebo-treated patients with heart failure. No significant
differences between the efficacy of the administration of coenzyme Q10 and placebo in the
endpoints of left heart ejection fraction and NYHA classification were observed.

Keywords: Cardiac failure; Coenzyme Q10; Exercise capacity; Placebo.

Conflict of interest statement

Ethics approval and consent to participate
As this is a meta-analysis, ethics approval and consent to participate were not required.

Consent for publication

Not Applicable.

Competing interests
All authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and
institutional affiliations.

Figures

Fig. 1 Flow chart Fig. 2 Forest plot of Fig. 3 Forest plot of left
showing the progress… mortality heart…

Fig. 4 Forest plot of Fig. 5 Forest plot of Fig. 6 Sensitivity

exercise capacity NYHA classification analysis

Similar articles
Coenzyme Q10 for heart failure.
Madmani ME, Yusuf Solaiman A, Tamr Agha K, Madmani Y, Shahrour Y, Essali A, Kadro W.
Cochrane Database Syst Rev. 2014 Jun 2;(6):CD008684. doi: 10.1002/14651858.CD008684.pub2.
PMID: 24049047 Review.

Ivabradine Improves Cardiac Function and Increases Exercise Capacity in Patients with
Chronic Heart Failure.
Pei H, Miao W, Xie WZ, Wang W, Zhao D, Su GH, Zhao Z.
Int Heart J. 2019 Jul 27;60(4):899-909. doi: 10.1536/ihj.18-559. Epub 2019 Jul 12.
PMID: 31308326

Efficacy and Safety of Inorganic Nitrate Versus Placebo Treatment in Heart Failure with
Preserved Ejection Fraction.
Gui Y, Chen J, Hu J, Ouyang M, Deng L, Liu L, Sun K, Tang Y, Xiang Q, Xu J, Zhu L, Peng Z, Zou P, Li B, Zheng Z,
Xu D.
Cardiovasc Drugs Ther. 2020 Aug;34(4):503-513. doi: 10.1007/s10557-020-06980-4.
PMID: 32394177

Study protocol, randomized controlled trial: reducing symptom burden in patients with
heart failure with preserved ejection fraction using ubiquinol and/or D-ribose.
Pierce JD, Mahoney DE, Hiebert JB, Thimmesch AR, Diaz FJ, Smith C, Shen Q, Mudaranthakam DP, Clancy RL.
BMC Cardiovasc Disord. 2018 Apr 2;18(1):57. doi: 10.1186/s12872-018-0796-2.
PMID: 29606104 Free PMC article.

Drug treatment effects on outcomes in heart failure with preserved ejection fraction: a
systematic review and meta-analysis.
Zheng SL, Chan FT, Nabeebaccus AA, Shah AM, McDonagh T, Okonko DO, Ayis S.
Heart. 2018 Mar;104(5):407-415. doi: 10.1136/heartjnl-2017-311652. Epub 2017 Aug 5.
PMID: 28780577 Free PMC article. Review.

See all similar articles

Cited by 16 articles
Supplementary Therapeutic Possibilities to Alleviate Myocardial Damage Due to
Microvascular Dysfunction in Coronavirus Disease 2019 (COVID-19).
Medvegy M, Simonyi G.
Cardiol Ther. 2021 Apr 2:1-7. doi: 10.1007/s40119-021-00216-8. Online ahead of print.
PMID: 33811310 Free PMC article.

From Mitochondria to Atherosclerosis: The Inflammation Path.

Suárez-Rivero JM, Pastor-Maldonado CJ, Povea-Cabello S, Álvarez-Córdoba M, Villalón-García I, Talaverón-Rey
M, Suárez-Carrillo A, Munuera-Cabeza M, Sánchez-Alcázar JA.
Biomedicines. 2021 Mar 5;9(3):258. doi: 10.3390/biomedicines9030258.
PMID: 33807807 Free PMC article. Review.

Nutraceutical, Dietary, and Lifestyle Options for Prevention and Treatment of Ventricular
Hypertrophy and Heart Failure.
McCarty MF.
Int J Mol Sci. 2021 Mar 24;22(7):3321. doi: 10.3390/ijms22073321.
PMID: 33805039 Free PMC article. Review.

Depleted Myocardial Coenzyme Q10 in Cavalier King Charles Spaniels with Congestive
Heart Failure Due to Myxomatous Mitral Valve Disease.
Christiansen LB, Reimann MJ, Schou-Pedersen AMV, Larsen S, Lykkesfeldt J, Olsen LH.
Antioxidants (Basel). 2021 Jan 22;10(2):161. doi: 10.3390/antiox10020161.
PMID: 33499156 Free PMC article.

Statin Treatment in Specific Patient Groups: Role for Improved Cardiovascular Risk
Markers.
White AMB, Mishcon HR, Redwanski JL, Hills RD Jr.
J Clin Med. 2020 Nov 21;9(11):3748. doi: 10.3390/jcm9113748.
PMID: 33233352 Free PMC article. Review.

See all "Cited by" articles

References
1. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Jr, Drazner MH, Fonarow GC, Geraci SA,
Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, PE MB, JJ MM,
Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL. 2013
ACCF/AHA guideline for the management of heart failure: a report of the American College of
Cardiology Foundation/American Heart Association Task Force on Practice Guidelines[J] J Am
Coll Cardiol. 2013;62(16):e147–e239. doi: 10.1016/j.jacc.2013.05.019. - DOI - PubMed
2. Deedwania PC, Carbajal EV. Chapter 18. Congestive heart failure.In: Crawford MH, ed.
CURRENT diagnosis & treatment: cardiology.3rd edn. New York, NY: The McGraw-Hill
Companies; 2009.
3. Massie BM, Shah NB. Evolving trends in the epidemiologic factors of heart failure: rationale
for preventive strategies and comprehensive disease management[J] Am Heart J.
1997;133(6):703–712. doi: 10.1016/S0002-8703(97)70173-X. - DOI - PubMed
4. Mahmood SS, Wang TJ. The epidemiology of congestive heart failure: the Framingham Heart
Study perspective[J] Global heart. 2013;8(1):77–82. doi: 10.1016/j.gheart.2012.12.006. - DOI -
PMC - PubMed
5. Niklowitz P, Sonnenschein A, Janetzky B, Andler W, Menke T. Enrichment of coenzyme Q10 in
plasma and blood cells: defense against oxidative damage[J] Int J Biol Sci. 2007;3(4):257–
262. doi: 10.7150/ijbs.3.257. - DOI - PMC - PubMed

Show all 30 references

Publication types
Meta-Analysis

MeSH terms
Adult
Aged
Cardiovascular Agents / adverse effects
Cardiovascular Agents / therapeutic use*
Chi-Square Distribution
Exercise Tolerance / drug effects
Female
Heart Failure / diagnosis
Heart Failure / drug therapy*
Heart Failure / mortality
Heart Failure / physiopathology
Humans
Male
Middle Aged
Odds Ratio
Randomized Controlled Trials as Topic
Recovery of Function
Risk Factors
Stroke Volume / drug effects
Treatment Outcome
Ubiquinone / adverse effects
Ubiquinone / analogs & derivatives*
Ubiquinone / therapeutic use
Ventricular Function, Left / drug effects

Substances
Cardiovascular Agents
Ubiquinone
coenzyme Q10

Related information
MedGen
PubChem Compound (MeSH Keyword)

LinkOut - more resources

Full Text Sources
BioMed Central
Europe PubMed Central
PubMed Central

Other Literature Sources

scite Smart Citations

Medical
MedlinePlus Health Information

Research Materials
NCI CPTC Antibody Characterization Program

Miscellaneous
NCI CPTAC Assay Portal

NCBI Literature Resources MeSH PMC BookShelf

FOLLOW NCBI

Follow NLM

National Library of Medicine

8600 Rockville Pike
Bethesda, MD 20894

Copyright
FOIA
Privacy

Help
Accessibility
Careers

NLM NIH HHS USA.gov